Biotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.
Next-gen antibody formats presented at PEGS Europe
Latest NewsBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.
Harbinger Health to speed up clinical cancer test validation
Latest NewsUS spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study aims to validate a blood test that predicts tumour developement in cancer stage I.
Novo Nordisk signs deal for monthly GLP-1 agonist
Latest NewsNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
Transgene and ProBioGen forge partnership
Latest NewsThe Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccines.
Novo’s obesity blockbuster semaglutide before label extension
Latest NewsIn both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
CEO and Chairman of the Executive Board
AppointmentsFrench Innate Pharma SA announced the appointment of Jonathan Dickinson as the Company’s newChief Executive Officer (CEO) and Chairman of the Executive Board. He succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.
Blue Therapeutics gets financing to push radiotherapies
Latest NewsRadiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1.
Enifer files for EFSA authorisation of mycoprotein
Latest NewsAs the first Nordic company seeking Novel Food approval for a mycoprotein ingredient, Finnish Enifer has filed a authorisation application for it brand PEKILO to the EU food watchdog EFSA.
Next European Biotechnology Guide 2026
euro-guideThe “16th European Biotechnology Science & Industry Guide 2026” – the handbook will present the strengths and core competencies of companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing in Europe. Besides the printed version the guide will also be available as a digital version.
AIgnostics raises US$34m in Series B financing
Latest NewsDigital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and to develop and offer new services for target and biomarker identification selection, particularly in the US pharma market.